> ## Documentation Index > Fetch the complete documentation index at: https://docs.insighthread.com/llms.txt > Use this file to discover all available pages before exploring further. # Insighthread News API: All Event Categories Reference > Complete list of the 35+ event categories returned by the Insighthread News API, each sourced from specific SEC filing types and sections. Every event returned by the Insighthread News API belongs to one of 35+ structured categories. Insighthread's extraction pipeline maps each SEC filing — down to the specific item section — to a category, so you always know what kind of event you're handling before you read a single word of the summary. Categories are available as filter parameters on the `/events` endpoint and are included in the `event_type` field of every event object. ## Filtering by Category Pass the `event_type` query parameter to the `/events` endpoint to receive only events matching a specific category. URL-encode values that contain spaces or special characters: ```bash theme={null} curl "https://api.insighthread.com/v1/events?event_type=FDA+Approval%2FRejections" \ -H "Authorization: Bearer YOUR_API_KEY" ``` You can combine `event_type` with other filters — such as `ticker`, `impact_min`, or `from` / `to` date range — to narrow results further. See [GET /events](/api/events) for the complete parameter reference. Use the `event_type` filter to subscribe your platform to only the categories relevant to your users. An equity trading desk, for example, might filter to `Mergers and Acquisitions`, `Bankruptcy/Liquidation`, and `Corporate Earnings`, while a pharma-focused fund would add `FDA Approval/Rejections`, `Drug Trial/Clinical Data`, and `Drug Updates`. ## Full Category List The table below lists all 35+ event categories, their descriptions, and the SEC filing types they are typically sourced from. | Category Name | Description | Common Filing Types | | -------------------------------------------- | -------------------------------------------------------------------------------------------------------- | ---------------------- | | **Bankruptcy/Liquidation** | Company files for bankruptcy protection or initiates formal liquidation proceedings | 8-K (1.03), 15-12B | | **C-Level Change** | CEO, CFO, COO, or other named executive officer departs, is appointed, or changes role | 8-K (5.02) | | **Corporate Earnings** | Quarterly or annual earnings release, including revenue, EPS, and guidance | 8-K (2.02), 10-Q, 10-K | | **Credit Ratings** | Credit rating upgrade, downgrade, placement on watch, or outlook change by a ratings agency | 8-K (8.01) | | **Deal Termination** | A previously announced merger, acquisition, partnership, or deal is formally cancelled | 8-K (1.02) | | **Delisting** | Company receives a delisting notice or non-compliance warning from a stock exchange | 8-K (3.01) | | **Dividends** | Dividend declaration, increase, reduction, suspension, or special dividend announced | 8-K (8.01) | | **Drug Trial/Clinical Data** | Clinical trial results, interim data readouts, or phase completion disclosures | 8-K (8.01) | | **Drug Updates** | FDA submission, new drug application (NDA), biologics license application (BLA), or pipeline update | 8-K (8.01) | | **Earnings Revision Guidance** | Company revises previously issued earnings or revenue guidance — upward or downward | 8-K (7.01) | | **Equity/Debt Offerings** | New share issuance, secondary offering, convertible note, or bond offering announced or priced | 8-K (1.01), S-1, S-3 | | **ESG** | Environmental, social, or governance disclosures, commitments, or incidents | Various | | **FDA Approval/Rejections** | FDA grants approval for a drug or medical device, or issues a complete response letter (CRL) | 8-K (8.01) | | **Geopolitics/Market News** | Macro-level geopolitical or market events that directly impact the company's operations or outlook | 8-K (8.01) | | **IPO News** | IPO pricing, S-1 filing, listing date announcement, or post-IPO lock-up expiration | S-1, 8-K | | **Insider Buy/Sell** | Named executive officer or director purchases or sells company shares | Form 4, Form 3 | | **Institutional New Position/Exit/Increase** | Institutional investor initiates, exits, or materially increases a position in the company | 13F, SC 13G/D | | **Legal Action** | New lawsuit filed against or by the company, or notice of government investigation | 8-K (8.01) | | **Litigation/Settlement** | Legal settlement reached, case dismissed, or judgment issued | 8-K (8.01) | | **Loans/Revolvers** | New credit facility entered, revolving credit line amended, or existing debt refinanced | 8-K (1.01) | | **Mergers and Acquisitions** | Merger agreement, acquisition announcement, or binding letter of intent for a strategic combination | 8-K (1.01) | | **Mining and Exploration** | Mineral resource discovery, exploration update, or reserve estimate revision | 8-K (7.01) | | **Minority Stakes Deals** | Partial equity stake acquisition in or by the company, below full acquisition threshold | 8-K (1.01) | | **Name Change** | Company legally changes its name or ticker symbol on a stock exchange | 8-K (5.03) | | **New Projects/Ventures** | Major new business initiative, product launch, joint venture, or strategic partnership announced | 8-K (8.01) | | **Operations Update** | Significant operational development such as a plant closure, production change, or supply chain event | 8-K (7.01) | | **Property Transaction** | Real estate acquisition, disposal, sale-leaseback, or major lease signing | 8-K (1.01) | | **Regulatory Action** | Action taken by a government agency or regulator — fine, consent order, investigation, or sanction | 8-K (8.01) | | **Restructuring** | Formal restructuring plan announced including layoffs, business unit closures, or organizational changes | 8-K (2.05) | | **Shareholder Activism** | Activist investor files a position, issues a public letter, or nominates board candidates | SC 13D | | **Staffing/Adds/Cuts** | Significant workforce hiring program or reduction-in-force (RIF) announcement | 8-K (2.05) | | **Stock Buybacks** | Share repurchase program announced, expanded, or completed | 8-K (8.01) | | **Trading Update** | Trading halt, suspension, resumption, or exchange circuit-breaker event affecting the company's shares | 8-K (3.01, 8.01) | ## Related topics - [Insighthread News API: Full Response Schema Reference](/api/response-schema.md) - [Insighthread News API: Real-Time SEC Event Intelligence](/api/overview.md) - [Insighthread News Feed: Real-Time SEC Filing Events](/features/news-feed.md) - [Monitor Market-Moving Events in Your Insighthread Feed](/guides/monitor-events.md) - [GET /events — Retrieve Real-Time SEC Market Events](/api/events.md)